IN VITRO AND IN VIVO EFFECT OF AN ORAL IRON CHELATOR DEFERASIROX IN MYELOID LEUKEMIA CELLS

被引：0
|
作者：
Choi, C. W. [1 ]
Kim, J. L. [2 ]
Kang, H. N. [2 ]
Kang, M. H. [2 ]
Yoo, Y. A. [2 ]
机构：
[1] Korea Univ, Guru Teg Bahadur Hosp, Seoul, South Korea
[2] Korea Univ, Coll Med, Grad Sch Med, Seoul 136705, South Korea
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0639
引用
收藏
页码：268 / 268
页数：1
相关论文
共 50 条
  • [41] Iron overload in patients with MDS: Baseline data from studies of the once-daily oral iron chelator, deferasirox
    Baer, R.
    Esposito, J.
    Kang, B.
    Virkus, J.
    Paley, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 379 - 380
  • [42] Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro
    Satoshi Imanishi
    Ryoko Takahashi
    Miho Ohsuga
    Kazuma Ohyashiki
    Junko H. Ohyashiki
    Annals of Hematology, 2015, 94 : 1601 - 1602
  • [43] Deferasirox, an iron chelator, impacts myeloid differentiation by modulating NF-kB activity via mitochondrial ROS
    Jeffries, Nathan E.
    Sadreyev, Daniel
    Trull, Elizabeth C.
    Chetal, Kashish
    Yvanovich, Emma E.
    Mansour, Michael K.
    Sadreyev, Ruslan I.
    Sykes, David B.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (05) : 2000 - 2007
  • [44] Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo
    Serhan, Nizar
    Mouchel, Pierre-Luc
    de Medina, Philippe
    Segala, Gregory
    Mougel, Aurelie
    Saland, Estelle
    Rives, Arnaud
    Lamaziere, Antonin
    Despres, Gaetan
    Sarry, Jean-Emmanuel
    Larrue, Clement
    Vergez, Francois
    Largeaud, Laetitia
    Record, Michel
    Recher, Christian
    Silvente-Poirot, Sandrine
    Poirot, Marc
    CANCERS, 2020, 12 (07) : 1 - 16
  • [45] Treatment with the once-daily, oral iron chelator deferasirox is effective and well tolerated in β-thalassaemia patientswith a high iron burden
    Taher, A.
    El-Beshlaw, A.
    Al Jefri, A.
    Elalfy, M.
    Al Zir, K.
    Daar, S.
    Damanhouri, G.
    Krahn, U.
    Pfluger, D.
    Hadler, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 302 - 302
  • [46] The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload
    Sivgin, Serdar
    Baldane, Suleyman
    Akyol, Gulsah
    Keklik, Muzaffer
    Kaynar, Leylagul
    Kurnaz, Fatih
    Pala, Cigdem
    Zararsiz, Gokmen
    Cetin, Mustafa
    Eser, Bulent
    Unal, Ali
    TRANSFUSION AND APHERESIS SCIENCE, 2013, 49 (02) : 295 - 301
  • [47] In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus
    G. P. Neupane
    D.-M. Kim
    European Journal of Clinical Microbiology & Infectious Diseases, 2010, 29 : 407 - 410
  • [48] In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus
    Neupane, G. P.
    Kim, D-M.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2010, 29 (04) : 407 - 410
  • [49] Beneficial effect of dipyridyl, a liposoluble iron chelator against focal cerebral ischemia:: In vivo and in vitro evidence of protection of cerebral endothelial cells
    Megthy, Delphine
    Bertrand, Nathalie
    Prigent-Tessier, Anne
    Mossiat, Claude
    Stanimirovic, Danica
    Beley, Alain
    Marie, Christine
    BRAIN RESEARCH, 2008, 1193 : 136 - 142
  • [50] Effect of oral iron chelator L1 on iron absorption in man
    Dresow, B
    Fischer, R
    Nielsen, P
    Gabbe, EE
    Piga, A
    COOLEYS ANEMIA: SEVENTH SYMPOSIUM, 1998, 850 : 466 - 468
12345